Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 30;12:715023. doi: 10.3389/fimmu.2021.715023

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Guo, Gao, Gao, Zhang, Jin, Fan, Wang, Li, Chen and Zhu

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Elevation of lymphocytopenia enhanced the risk of secondary infection. The levels of CD4+ (A), CD8+ (B), CD3+ (C), CD19+ (D), CD16+CD56+ (E) and CD4+/CD8+ (F) ratio in mild/moderate COVID-19, severe/critical COVID-19 without risk of secondary infection and severe/critical COVID-19 with the risk of secondary infection were shown. Each group of samples was further divided into three groups according to the time post-symptoms, including day 0 to day 9, day 10 to day 30, and post day 30. The barplot patients with the risk of secondary infection at day 0 to day 9 were not shown due to no available data. The chosen level of statistically significance were *P < 0.01 and **P < 0.05, respectively.